US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children
Closed Posted
- Opportunity number
- RFA-IP-21-002
- Agency
-
Centers for Disease Control and Prevention
Department of Health and Human Services
- Applications due
- Award size
- $1,600,000 to $1,950,000
Opportunity facts
- Assistance listings
- Funding instrument
- Cooperative Agreement
- Category
-
- Health
- Eligible applicants
-
- County Governments
- Higher Education Inst. (Public)
- Public or Indian Housing Auth.
- Special District Governments
- 501(c)(3) Nonprofits
- Other
- Tribal Governments (Federally Recognized)
- Non-501(c)(3) Nonprofits
- Independent School Districts
- City/Township Governments
- Tribal Organizations (Not Federally Recognized)
- State Governments
Opportunity details come from Grants.gov. Updated .
Synopsis
The goal of this Notice of Funding Opportunity (NOFO) is to support a network of US institutions to develop and implement standard research protocols to conduct prospective active surveillance for: a) acute gastroenteritis (AGE) due to norovirus, rotavirus and other enteric viruses; b) acute respiratory illnesses (ARI) due to respiratory viruses including, but not limited to, influenza, RSV, parainfluenza viruses, human metapneumovirus, rhinoviruses, enteroviruses (including EV-D68), adenoviruses, and coronaviruses (including SARS-CoV-2); and c) acute flaccid myelitis (AFM) syndrome and multisystem inflammatory syndrome in children (MIS-C) among pediatric patients seeking healthcare at medical institutions. The network should also provide accurate estimates of the effectiveness in this population of influenza, rotavirus, COVID-19 and other vaccines against respiratory or enteric virus-associated illnesses projected to become available during the period of performance (e.g., RSV, norovirus). Participating institutions should identify AGE, ARI, AFM and MIS-C illnesses among pediatric patients seeking healthcare or diagnostic testing for acute illness in inpatient, outpatient and emergency departments. Recipients should enroll patients meeting standard symptom criteria, and confirm viral infection using approved molecular assays. Vaccine effectiveness (VE) estimates will be calculated. Estimates of VE, burden of disease, and information on the natural history of disease will be used to: a) inform best practices for diagnosis and treatment protocols; b) inform vaccine recommendations; and c) assess public health impact of vaccination and public health programs to prevent viral illness-related healthcare encounters and medical visits among pediatric populations.
Files
| File | Type | Posted |
|---|---|---|
| RFA-IP-21-002.pdf | ||
| RFA-IP-21-002 Amend 1.pdf | ||
| RFA-IP-21-002 Amend 1 03 03 21 .pdf | ||
| RFA-IP-21-002.pdf | ||
| PKG00264149-instructions.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity